sgusers10的部落格

NEW YORK, Sept.迷你倉 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Leading Anti-Cancer Drugs and Associated Market 2013-2023 .reportlinker.com/p0819459/Leading-Anti-Cancer-Drugs-and-Associated-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_MedicationReport DetailsCancer treatments - here's your guide to R&D and sales potentialsDo you want to assess the future of cancer medicines? Visiongain's updated report gives you revenue predictions there from 2013, helping you stay ahead. You find financial data, R&D trends, opportunities, and outlooks.In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging trends, technologies, and expected drugs.You see what shapes that industry and find its revenue prospectsDiscover, then, what the future holds for anti-cancer products. Read on to explore that industry and see what its future market could be worth.Forecasts to 2023 and other analyses show you commercial potentialsBesides revenue forecasting to 2023, you find historical data, growth rates, and market shares. You assess quantitative and qualitative analysis, business news, outlooks, and developments (R&D). You also gain 114 tables, 47 charts, and three interviews.Is finding data for cancer treatment a challenge? Our work lets you investigate the most promising and lucrative parts of applied oncology, helping you stay ahead in knowledge. That way, you reduce your risk of missing out. Finding data you need has just got easier.Many opportunities remain for cancer-treating drugs. Now see how you can benefit your research, analyses, and decisions there.The following sections show, then, how you benefit from our new investigation and analysis.Discover outlooks for the world market and submarketsAlong with prediction of overall world market value to 2023, our report shows you revenue forecasting of four submarkets at world level:-- Immunotherapies-- Targeted therapies-- Hormone-based agents-- Chemotherapies.Also our study discusses what stimulates and restrains business. That analysis helps you identify potential and find ways for your business to develop. Assess leading brands too.See forecasts for the leading 25 cancer-treating drugsHow will leading drugs perform to 2023 at world level? Our study forecasts individual revenues of the top 25 anti-cancer agents, including these products:-- Rituxan-- Herceptin-- Avastin-- Gleevec-- Revlimid-- Alimta-- Velcade.There you discover how high sales can go, to 2023, finding drugs and years with highest predicted growth and revenues. You see what's happening, then, understanding trends, competition, challenges, and opportunities. Also, assess drugs approved from 2012 to 2013.You find geographical revenue predictions too.Leading national markets - where lie highest revenues and growth? Developments worldwide expand the cancer drugs market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.In developed and developing countries, opportunities for pharma companies will occur from 2013. See where and how.Our analyses show you individual revenue forecasts to 2023 for 11 national markets:-- US-- Japan-- Germany, France, UK, Italy, and Spain (EU5)-- Brazil, Russia, India, and China (BRIC).You find potential. Our analyses show growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2013 to 2023 will change medical prescribing and the commercial landscape.Research and development - assess innovation, trends, and possibilitiesWhat's happening in oncological R&D? You see trends for treating these cancers:-- Bladder-- Brain-- Breast-- Cervix-- Gut-- Kidney-- Leukaemia-- Liver-- Lung.Our study also discusses products in development for these cancers:-- Lymphoma-- Multiple myeloma-- Ovary-- Pancreas-- Prostate-- Sarcoma and skin-- Stomach-- Other cancers.R&D in oncology holds strength, variety, and promise. You assess innovations, hearing about developments and finding their significance. Discover progress.For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing issues to help your work. Also, see what shapes the market from 2013.What affects the industry and market for anti-cancer drugs? Our report discusses issues and events affecting that industry and market from 2013, including these:-- Epidemiology - incidence, prevalence, mortality, and survival-- Tumour (tumor) resistance, heterogeneity, and other medical challenges-- Personalised medicine, live licensing, and theranostics-- Cost-effectiveness, pricing, and reimbursement-- Payers and healthcare policy.The study also discusses other aspects of cancer treatment, including these:-- Monoclonal antibodies (mAbs), cancer vaccines, and other technologies-- Efficacy, toxicity, and alternative treatments-- Biosimilars (follow-on-protein products) and generics-- Pharmacogenomics and genome screening-- Biomarkers and diagnostics.That way, you explore technological, economic, social, and political (STEP) questions, assessing outlooks for the business. You also analyse the anti-cancer drug industry's strengths, weaknesses, opportunities, and threats (SWOT).See, then, what the future holds.Leading companies in cancer treatment and 2017 market valueFrom 2013, new treatments hold great potential for investment, technological advances and high revenues. Our report predicts the world market for anti-cancer agents will reach $116.5bn in 2017, and expand further to 2023.Our analyses show you what technologies, products, and organisations hold greatest potential. They cover these leading companies, among others:-- Roche-- Novartis-- Celgene-- AstraZeneca-- Eli Lilly-- Merck & Co.Prospects for R&D in oncology are strong, and from 2013 there will arise many opportunities. Our work shows you possibilities, helping you stay ahead.Nine ways Leading Anti-Cancer Drugs and Associated Market 2013-2023 helps youIn particular, then, our investigation gives you the following knowledge:-- Revenue to 2023 for the world anti-cancer drugs market - discover that industry's overall sales potential-- Revenues to 2023 for 4 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and revenues-- Revenues to 2023 for 25 leading products - find sales outlooks for top brands, seeing how they can compete and succeed-- Forecasts to 2023 for 11 leading national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth-- Assessments of leading companies - hear about participants' activities, capabilities, results, and outlooks-- Review of R&D in oncology - explore progress in research and development, finding technological and clinical possibilities-- Interviews with authorities in the field - discover debates and opinions to help you stay ahead-- Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages-- Competition and opportunities - investigate what shapes that market's future, including ways to develop business.You gain information found nowhere elseThat work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions, also saving time.Discover potential now in anti-cancer medicines and see what you can gain.Ordering now lets you discover opportunities and predictions for cancer treatmentsOur new study is for everyone analysing the industry and market for pharmaceutical biotechnology and cancer medicines. There you find data, trends, opportunities, and predictions. Avoid missing out - please order our report now.Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6Table of Contents1. Executive Summary1.1 Overview of Findings1.2 Chapter Breakdown1.3 Research and Analysis Methods1.4 Scope of the Report2. Introduction to Cancer Treatment2.1 The Physiology of Cancer - Causes and Effects2.1.1 Uncontrolled Growth2.1.2 Dedifferentiation2.1.3 Invasiveness and Metastasis2.1.4 Causes of Cancer2.2 The Incidence and Prevalence of Cancer - Rapid Global Growth2.2.1 Incidence2.2.2 Mortality2.2.3 Survival - Improving Odds2.2.3.1 The Developed World2.2.3.2 The Developing World - More Must Be Done2.3 Treating Tumours - How Can We Fight Back?2.3.1 Chemotherapy - The Traditional Treatment2.3.2 Hormone Therapies2.3.3 Immunotherapy - A Magic Bullet2.3.3.1 Monoclonal Antibodies (mAbs)2.3.3.2 Cancer Vaccines2.3.3.3 Non-Specific Immunotherapies2.3.4 Targeted Therapies2.3.5 Differentiating Agents3. World Anti-Cancer Drug Market, 2013-20233.1 Immunotherapies' Market Domination in 20123.2 Global Anti-Cancer Drugs Market Forecast, 2013-20233.3 Immunotherapy Market Forecast, 2013-2023 -The Fastest Growing Anti-Cancer Segment3.4 Targeted Therapy Market Forecast, 2013-2023 - Another Robust Driver of Growth3.5 Hormone Therapy Forecast, 2013-2023 - Dependably Solid3.6 Chemotherapy Market Forecast, 2013-2023 - A Major Contributor4. Leading National Markets, 2013-20234.1 Anti-Cancer Drugs - Leading National Markets, 20124.2 The US Anti-Cancer Drug Market, 2013-2023 - Continued Leadership or Terminal Decline?4.3 The Japanese Anti-Cancer Drug Market, 2013-20234.4 The Leading Five Anti-Cancer Drug Markets in the EU (EU5), 2013-2023 - Serious Competitors to the US Market?4.5 Anti-Cancer Drug Markets in BRIC Countries, 2013-2023 - Awakening Sleeping Giants?4.5.1 Brazil, 2013-2023- BRIC's Smallest Market4.5.2 Russia, 2013-2023 - Rising Cancer Rates Drive Growth4.5.3 India, 2013-2023 - Lucrative Opportunity for Growth4.5.4 China, 2013-2023 - Can This Market Fulfil Vast Potential?5. Top 25 Anti-Cancer Drugs: Market Prospects, 2013-20235.1 Rituxan/MabThera (Roche) - The World's Leader5.1.1 Rituxan Sales, 20125.1.2 Competition Facing Rituxan - David vs. Goliath5.1.3 Rituxan Sales Forecast, 2013-20235.2 Herceptin (Roche)5.2.1 Herceptin Sales, 20125.2.2 Competition Facing Herceptin - A Tough Act to Follow5.2.3 Rituxan Sales Forecast, 2013-20235.3 Avastin (Roche) - Slowing Growth5.3.1 Avastin Sales, 20125.3.2 Competition Facing Avastin - Many Newer Options5.3.3 Avastin Sales Forecast, 2013-20235.4 Gleevec (Novartis)5.4.1 Gleevec Sales, 20125.4.2 Competition Facing Gleevec - Looming Generic Challengers5.4.3 Gleevec Sales Forecast, 2013-20235.5 Revlimid (Celgene) - Celgene's Main Revenue Generator5.5.1 Revlimid Sales, 20125.5.2 Competition Facing Revlimid - A Crowded Market5.5.3 Revlimid Sales Forecast, 2013-2023 - A Long-Term Leader?5.6 Alimta (Eli Lilly)5.6.1 Alimta Sales, 20125.6.2 Competition Facing Alimta - Strong Challengers Await5.6.3 Alimta Sales Forecast, 2013-2023 - Revenue Erosion Looming5.7 Velcade (Takeda/J&J)5.7.1 Velcade Sales, 20125.7.2 Competition Facing Velcade - A New Product to Worry About5.7.3 Velcade Sales Forecast, 2013-2023 - A Dependable Revenue Generator5.8 Gardasil (Merck & Co.) - One Vaccine to Dominate?5.8.1 Gardasil Sales, 20125.8.2 Competition Facing Gardasil - Only One Challenger That Matters5.8.3 Gardasil Sales Forecast, 2013-2023 - Merck's Revenue Generator5.9 Xeloda (Roche)5.9.1 Xeloda Sales, 20125.9.2 Competition Facing Xeloda - Is It Up To The Challenge?5.9.3 Xeloda Sales Forecast, 2013-20235.10 Tarceva (Roche)5.10.1Tarceva Sales, 20125.10.2 Competition Facing Tarceva - A Number of Other Options5.10.3 Tarceva Sales Forecast, 2013-2023 - An Excellent Return5.11 Sutent (Pfizer) - A Replacement for Gleevec5.11.1 Sutent Sales, 20125.11.2 Competition Facing Sutent5.11.3 Sutent Sales Forecast, 2013-2023 - Solid Sales for Several More Years5.12 Zoladex (AstraZeneca) - Prominent Hormone Therapy5.12.1 Zoladex Sales, 20125.12.2 Competition Facing Zoladex5.12.3 Zoladex Sales Forecast, 2013-20235.13 Sprycel (Bristol-Myers Squibb)5.13.1 Sprycel Sales, 2012 - Rapid Growth5.13.2 Competition Facing Sprycel5.13.3 Sprycel Sales Forecast, 2013-2023 - How Long Will the Growth Last?5.14 Nexavar (Bayer/Onyx)5.14.1 Nexavar Sales, 2012- Stalled Growth?5.14.2 Competition Facing Nexavar5.14.3 Nexavar Sales Forecast, 2013-2023 - More Years of Success5.15 Tasigna (Novartis)5.15.1 Tasigna Sales, 2012 - Blockbuster Revenue5.15.2 Competition Facing Tasigna5.15.3 Tasigna Sales Forecast, 2013-2023 - A Multi-Billion Dollar Product?5.16 Eloxatin (Sanofi)5.16.1 Eloxatin Sales, 20125.16.2 Competition Facing Eloxatin - Looming Patent Expiry5.16.3 Eloxatin Sales Forecast, 2013-20235.17 Temodar/Temodal (Merck & Co.)5.17.1 Temodar Sales, 20125.17.2 Competition Facing Temodar5.17.3 Temodar Sales Forecast, 2013-2023 - Generic Competition Awaits5.18 Vidaza (Celgene)5.18.1 Vidaza Sales, 20125.18.2 Competition Facing Vidaza - Generic Competitor a Matter of Time5.18.3 Vidaza Sales Forecast, 2013-20235.19 Afinitor (Novartis) - A Breast Cancer Breakthrough5.19.1 Afinitor Sales, 2012 - Another Success5.19.2 Competition Facing Afinitor5.19.3 Afinitor Sales Forecast, 2013-20235.20 Xgeva (Amgen)5.20.1 Xgeva Sales, 2012- Massive Growth in Sales5.20.2 Competition Facing Xgeva5.20.3 Xgeva Sales Forecast, 2013-2023 - Expectations Are High5.21 Taxotere (Sanofi)5.21.1 Taxotere Sales, 2012 - How Rapid a Revenue Erosion?5.21.2 Competition Facing Taxotere5.21.3 Taxotere Sales Forecast, 2013-20235.22 Yervoy (Bristol-Myers Squibb)5.22.1 Yervoy Sales, 2012 - Revenue Expansion Possible5.22.3 Competition Facing Yervoy5.22.3 Yervoy Sales Forecast, 2013-2023 - How Many Years of Growth Await?5.23 Erbitux (Bristol-Myers Squibb)5.23.1 Erbitux Sales, 20125.23.2 Competition Facing Erbitux5.23.3 Erbitux Sales Forecast, 2013-2023 - Gradual Drop in Revenues Expected5.24 Faslodex (AstraZeneca) - Zoladex's Counterpart5.24.1 Faslodex Sales, 2012 - Europe and Japan Lead the Way5.24.2 Competition Facing Faslodex5.24.3 Faslodex Sales Forecast, 2013-20235.25 Treanda (Teva Pharmaceuticals)5.25.1 Treanda Sales, 20125.25.2 Competition Facing Treanda5.25.3 Treanda Sales Forecast, 2013-2023 - Stalled Revenue Growth?6. Drugs Approved 2012-2013: Tomorrow's Blockbusters? 6.1 FDA-Approved Treatments in 20136.1.1 Kadcyla (Roche): A Potential Game-Changer6.1.1.1 Market Potential6.1.2 Pomalyst (Celgene)6.1.2.1 Market Potential: An Addition to a Crowded Market6.2 FDA-Approved Treatments in 2012: Rise of the Targeted Therapies6.2.1 Abraxane (Celgene)6.2.1.1 Market Potential: A Lower-Cost Alternative to Existing Treatments6.2.2 Afinitor (Novartis)6.2.2.1 Market Potential: More Indications, Greater Revenues?6.2.3 Bosulif (Pfizer): Pfizer's Answer to Novartis6.2.3.1 Market Potential6.2.4 Cometriq (Exelixis)6.2.4.1 Market Potential: Welcome Addition to an Open Market6.2.5 Erivedge (Roche): A Future Blockbuster?6.2.5.1 Market Potential6.2.6 Iclusig (Ariad Pharmaceuticals)6.2.6.1 Market Potential: A Capable Alternative to Gleevec6.2.7 Inlyta (Pfizer)6.2.7.1 Market Potential: Just Another Tyrosine Kinase Inhibitor?6.2.8 Krypolis (Onyx Pharmaceuticals)6.2.8.1 Market Potential: Stiff Competition May Blunt Growth6.2.9 Marqibo (Talon Therapeutics)6.2.9.1 Market Potential6.2.10 Perjeta (Roche)6.2.10.1 Market Potential6.2.11Stivarga (Bayer HealthCare Pharmaceuticals)6.2.11.1 Market Potential: Another Option for Patients6.2.12 Synribo (Teva Pharmaceuticals)6.2.12.1 Market Potential: A Potential Cash Cow6.2.13 Votrient (GlaxoSmithKline): GSK's Newest Entry6.2.13.1 Market Potential6.2.14 Xtandi (Medivation): Prostate Cancer's Newest Foe6.2.14.1 Market Potential6.2.15 Zaltrap (Sanofi):6.2.15.1 Market Potential: Sanofi's Newest Anti-Cancer Winner?7. Leading Companies for Cancer Treatments, 20137.1 Anti-Cancer Drug Market Dominated by Six Companies7.2 Roche - The World's Foremost Oncology Company7.2.1 Oncology Pipeline - Investment in the Future7.2.2 Future Directions in Cancer Treatment7.3 Novartis - Tomorrow's Leader?7.3.1 Oncology R&D Pipeline - What's the Po儲存ential?7.3.2 Future Directions in Cancer Treatment7.4 Celgene - Pressing Need to Diversify?7.4.1 Oncology Pipeline - Safeguarding Celgene's Future7.4.2 Future Directions in Cancer Treatment7.5 AstraZeneca - A Well-Balanced Portfolio7.5.1 Oncology Pipeline - Showing Promise7.5.2 Future Directions in Cancer Treatment7.6 Eli Lilly - How Strong is its Contribution to the Market?7.6.1 Oncology Pipeline - What Potential Exists?7.6.2 Future Directions in Cancer Treatment7.7 Merck & Co. - Prominent in Vaccines7.7.1 Oncology Pipeline - Greater Focus on Oncology7.7.2 Future Directions in Cancer Treatment8. R&D Pipelines for Cancer Treatment8.1 Bladder Cancer Drugs Under Development8.1.1 Profile: EOquin (Allergan)8.2 Brain Cancer Drugs Under Development8.2.1 Profile: Rindopepimut (Celldex Therapeutics)8.3 Breast Cancer Drugs Under Development8.3.1 Afatinib (Boehringer Ingelheim)8.4 Cervical Cancer Drugs Under Development8.4.1 Profile: V503 (Merck & Co.)8.5 Colorectal Cancer Drugs Under Development8.5.1 Aptocine (Light Sciences Oncology)8.6 Kidney Cancer Drugs Under Development8.6.1 Rencarex (Wilex)8.7 Leukaemia Drugs Under Development8.7.1 Obinutuzumab (Roche)8.8 Liver Cancer Drugs Under Development8.8.1 Brivanib (Bristol-Myers Squibb)8.9 Lung Cancer Drugs Under Development8.9.1 BIBF 1120 (Boehringer Ingelheim)8.10 Lymphoma Drugs Under Development8.10.1 Inotuzumab Ozogamicin (Pfizer)8.11 Multiple Myeloma Drugs Under Development8.11.1 LBH589 (Novartis)8.12 Ovarian Cancer Drugs Under Development8.12.1 AMG 386 (Amgen)8.13 Pancreatic Cancer Drugs Under Development8.13.1 AMG 479 (Amgen)8.14 Prostate Cancer Drugs Under Development8.14.1 MDV-3100 (Astellas Pharma US/Medivation)8.15 Sarcoma Drugs Under Development8.15.1 Mifamurtide (Millennium Pharmaceuticals)8.16 Skin Cancer Drugs Under Development8.16.1 Allovectin (Vical)8.17 Stomach Cancer Drugs Under Development8.17.1 Ramucirumab (Eli Lilly/ImClone Systems)8.18 Other Cancer Drugs Under Development8.18.1 Lenvatinib (Eisai)9. SWOT and STEP Analyses, 20139.1 Strengths of the Industry and Market9.1.1 High Profile of Cancer9.1.2 Off-Label Prescriptions Common9.1.3 Drug Development Incentives9.2 Weaknesses of the Industry and Market9.2.1 Tumour Resistance9.2.2 Pricing-Out the Developing World?9.3 Opportunities for the Industry and Market9.3.1 Rising Incidence of Cancer9.3.1.1 Ageing Populations9.3.1.2 Smoking9.3.1.3 Obesity9.3.1.4 The Developing World9.3.2 Personalised Medicine9.3.3 Live Licensing9.3.4 Convenient Drugs9.4 Threats Facing the Industry and Market9.4.1 The Cost-Effectiveness Debate9.4.2 Governments: Leading Payers for Drugs9.4.3 Efficacy, Toxicity and Alternative Treatments9.5 Biosimilars and Generics: Opportunity or Threat?9.6 Personalised Medicine9.6.1 Cancer Heterogeneity9.6.2 Pharmacogenomics9.6.3 Genome Screening9.6.4 Biomarkers and Diagnostics9.6.5 Theranostics10. Research Interviews10.1 Interview with Dr Sidong Huang, Assistant Professor of Biochemistry at McGill University10.1.1 On His Research Interests and their Utility in Anti-Cancer Drug Development10.1.2 On the Evaluation of New Targets for Anti-Cancer Drugs10.1.3 On Drug Resistance and Targeted Therapies10.1.4 On the Future of Traditional Chemotherapy10.1.5 On Future Developments in the Anti-Cancer Field10.2 Interview with Dr Neil Butt, Director, Antitope Ltd.10.2.1 On Immunogenicity in Therapeutic Proteins10.2.2 On Antitope's Technologies to Assess and Reduce Immunogenicity10.2.3 On an Alternative Way of Reducing Immunogenicity10.2.4 On Biosimilars10.2.5 On Future Developments in this Field10.3 Interview with Dr Kent C. Osborne, Baylor College of Medicine10.3.1 On Challenges in Developing Anti-Cancer Therapies10.3.2 On Major Areas of Focus10.3.3 On Cancer Vaccines10.3.4 On Areas with Potential for Increased Revenue Generation10.3.5 On the R&D Pipeline10.3.6 On Difficulties Conducting Clinical Trials11. Conclusions11.1 Top 25 Drugs in the World Cancer Treatment Market11.2 Immunotherapies - The Driving Force11.2.1 Biosimilars Have Potential in Emerging Markets11.3 The US- the Largest Anti-Cancer Drug Market11.4 India and China Will be the Fastest-Growing National Markets11.5 Personalised Medicine - the Future of Cancer Therapy11.6 Anti-Cancer Drug Pipeline Remains Strong11.7 Concluding RemarksList of TablesTable 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2013Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2013Table 3.1 Global Anti-Cancer Market Sales ($bn), Annual Growth Rates (%) and Market Shares (%) by Segment, 2011 and 2012Table 3.2 Global Anti-Cancer Market Forecast ($bn), 2012-2013Table 3.3 Global Anti-Cancer Drug Market: Revenue Forecasts by Category ($bn), 2012-2023Table 3.4 Global Anti-Cancer Market: Drivers and Restraints, 2013Table 3.5 Global Immunotherapies Market ($bn), 2012Table 3.6 Immunotherapy Market Forecast ($bn), 2012-2023Table 3.7 Immunotherapy Market: Drivers and Restraints, 2013Table 3.8 Global Targeted Therapies Market ($bn), 2012Table 3.9 Targeted Therapies Market Forecast ($bn), 2012-2023Table 3.10 Targeted Therapies Market: Drivers and Restraints, 2013Table 3.11Hormone Therapy Market Forecast ($bn), 2012-2023Table 3.12 Hormone Therapy Market: Drivers and Restraints, 2013Table 3.13 Global Chemotherapies Market ($bn), 2012Table 3.14 Chemotherapy Market Forecast ($bn), 2012-2023Table 3.15 Chemotherapy Market: Drivers and Restraints, 2013Table 4.1 Anti-Cancer Drug Market by Leading Country ($bn), 2012, 2017 and 2023Table 4.2 Developed Markets: Drivers and Restraints, 2013Table 4.3 Emerging Markets: Drivers and Restraints, 2013Table 4.4 Global Anti-Cancer Drug Market: Forecasts by Leading Country ($bn), 2012-2023Table 4.5 US Anti-Cancer Drug Market Forecast ($bn), 2012-2023Table 4.6 Japanese Anti-Cancer Drug Market Forecast ($bn), 2012-2023Table 4.7 The Leading 5 EU Anti-Cancer Drug Markets: Forecasts ($bn), 2012-2023Table 4.8 BRIC Countries: Anti-Cancer Drug Markets: Forecasts ($bn), 2012-2023Table 5.1 Top 25 Anti-Cancer Drugs: Sales ($bn) and Market Shares (%), 2012Table 5.2 Top 5 Companies in the Anti-Cancer Drugs Market: Sales ($bn) and Market Shares (%), 2012Table 5.3 Top 25 Anti-Cancer Drugs: Sales Forecasts ($bn), 2012-2023Table 5.4 Top 25 Anti-Cancer Drugs: Sales Forecasts ($bn), 2012-2023 (Contd.)Table 5.5 Top 25 Anti-Cancer Drugs: Sales Forecasts ($bn), 2012-2023 (Contd.)Table 5.6 Rituxan Sales Forecast ($bn), 2012-2023Table 5.7 Rituxan: Sales Drivers and Restraints, 2013Table 5.8 Herceptin Sales Forecast ($bn), 2012-2023Table 5.9 Herceptin: Sales Drivers and Restraints, 2013Table 5.10 Avastin Sales Forecast ($bn), 2012-2023Table 5.11 Avastin: Sales Drivers and Restraints, 2013Table 5.12 Gleevec Sales Forecast ($bn), 2012-2023Table 5.13 Gleevec: Sales Drivers and Restraints, 2013Table 5.14 Revlimid Sales Forecast ($bn), 2012-2023Table 5.15 Revlimid: Sales Drivers and Restraints, 2013Table 5.16 Alimta Sales Forecast ($bn), 2012-2023Table 5.17 Alimta: Sales Drivers and Restraints, 2013Table 5.18 Velcade Sales Forecast ($bn), 2012-2023Table 5.19 Velcade: Sales Drivers and Restraints, 2013Table 5.20 Gardasil Sales Forecast ($bn), 2012-2023Table 5.21 Gardasil: Sales Drivers and Restraints, 2013Table 5.22 Xeloda Sales Forecast ($bn), 2012-2023Table 5.23 Xeloda: Sales Drivers and Restraints, 2013Table 5.24 Tarceva Sales Forecast ($bn), 2012-2023Table 5.25 Tarceva: Sales Drivers and Restraints, 2013Table 5.26 Sutent Sales Forecast ($bn), 2012-2023Table 5.27 Sutent: Sales Drivers and Restraints, 2013Table 5.28 Zoladex Sales Forecast ($bn), 2012-2023Table 5.29 Zoladex: Sales Drivers and Restraints, 2013Table 5.30 Sprycel Sales Forecast ($bn), 2012-2023Table 5.31 Sprycel: Sales Drivers and Restraints, 2013Table 5.32 Nexavar Sales Forecast ($bn), 2012-2023Table 5.33 Nexavar: Sales Drivers and Restraints, 2013Table 5.34 Tasigna Sales Forecast ($bn), 2012-2023Table 5.35 Tasigna Sales Drivers and Restraints, 2013Table 5.36 Eloxatin Sales Forecast ($bn), 2012-2023Table 5.37 Eloxatin: Sales Drivers and Restraints, 2013Table 5.38 Temodar Sales Forecast ($bn), 2012-2023Table 5.39 Temodar Sales Drivers and Restraints, 2013Table 5.40 Vidaza Sales Forecast ($bn), 2012-2023Table 5.41 Vidaza Sales Drivers and Restraints, 2013Table 5.42 Afinitor Sales Forecast ($bn), 2012-2023Table 5.43 Afinitor Drivers and Restraints, 2013Table 5.44 Xgeva Sales Forecast ($bn), 2012-2023Table 5.45 Xgeva Drivers and Restraints, 2013Table 5.46 Taxotere Sales Forecast ($bn), 2012-2023Table 5.47 Taxotere: Sales Drivers and Restraints, 2013Table 5.48 Yervoy Sales Forecast ($bn), 2012-2023Table 5.49 Yervoy: Sales Drivers and Restraints, 2013Table 5.50 Erbitux Sales Forecast ($bn), 2012-2023Table 5.51 Erbitux: Sales Drivers and Restraints, 2013Table 5.52 Faslodex Sales Forecast ($bn), 2012-2023Table 5.53 Faslodex: Sales Drivers and Restraints, 2013Table 5.54 Treanda Sales Forecast ($bn), 2012-2023Table 5.55 Treanda: Sales Drivers and Restraints, 2013Table 7.1 Anti-Cancer Drug Sales ($bn) and Market Shares (%) by Leading Company, 2012Table 7.2 Roche Anti-Cancer Drugs: Sales ($bn), 2011-2012Table 7.3 Selected Drugs from Roche Oncology Pipeline, 2012Table 7.4 Novartis Anti-Cancer Drugs: Sales ($bn), 2011-2012Table 7.5 Novartis Oncology Pipeline, 2012Table 7.6 Celgene Anti-Cancer Drugs: Sales ($bn), 2011-2012Table 7.7 Celgene Oncology Pipeline, 2012Table 7.8 AstraZeneca Anti-Cancer Drugs: Sales ($bn), 2011-2012Table 7.9 Selected Drugs from AstraZeneca Oncology Pipeline, 2012Table 7.10 Eli Lilly Anti-Cancer Drugs: Sales ($bn), 2011-2012Table 7.11 Selected Drugs from Eli Lilly Oncology Pipeline, 2012Table 7.12 Merck & Co. Anti-Cancer Drugs: Sales ($bn), 2011-2012Table 7.13 Merck & Co. Oncology Pipeline, 2012Table 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2012Table 8.2 Bladder Cancer: Some Late Stage Drugs Under Development, 2012Table 8.3 Brain Cancer: Some Late Stage Drugs Under Development, 2012Table 8.4 Breast Cancer: Some Late Stage Drugs Under Development, 2012Table 8.5 Cervical Cancer: Some Late Stage Drugs Under Development, 2012Table 8.6 Colorectal Cancer: Some Late Stage Drugs Under Development, 2012Table 8.7 Kidney Cancer: Some Late Stage Drugs Under Development, 2012Table 8.8 Leukaemia: Some Late Stage Drugs Under Development, 2012Table 8.9 Liver Cancer: Some Late Stage Drugs Under Development, 2012Table 8.10 Lung Cancer: Some Late Stage Drugs Under Development, 2012Table 8.11 Lymphoma: Some Late Stage Drugs Under Development, 2012Table 8.12 Multiple Myeloma: Late Stage Drug Under Development, 2012Table 8.13 Ovarian Cancer: Some Late Stage Drugs Under Development, 2012Table 8.14 Pancreatic Cancer: Some Late Stage Drugs Under Development, 2012Table 8.15 Prostate Cancer: Some Late Stage Drugs Under Development, 2012Table 8.16 Sarcoma: Some Late Stage Drugs Under Development, 2012Table 8.17 Skin Cancer: Some Late Stage Drugs Under Development, 2012Table 8.18 Stomach Cancer: Some Late Stage Drugs Under Development, 2012Table 8.19 Other Cancers: Some Late Stage Drugs Under Development, 2012Table 9.1 SWOT Analysis of the Anti-Cancer Drugs Market, 2013Table 9.2 STEP Analysis of the Anti-Cancer Drug Market, 2013List of FiguresFigure 3.1 World Anti-Cancer Market Shares (%) by Segment, 2012Figure 3.2 Global Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 3.3 Global Anti-Cancer Market Shares (%) by Category, 2013Figure 3.4 Global Anti-Cancer Market Shares (%) by Category, 2023Figure 3.5 Immunotherapy Market Forecast ($bn), 2012-2023Figure 3.6 Targeted Therapies Market Forecast ($bn), 2012-2023Figure 3.7 Hormone Therapy Market Forecast ($bn), 2012-2023Figure 3.8 Chemotherapy Market Forecast ($bn), 2012-2023Figure 4.1 Anti-Cancer Drug Market Shares (%) by Leading Country, 2012Figure 4.2 Anti-Cancer Drug Market Shares (%) by Leading Country, 2017Figure 4.3 Anti-Cancer Drug Market Shares (%) by Leading Country, 2023Figure 4.4 US Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 4.5 Japanese Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 4.6 Leading 5 EU Anti-Cancer Drug Market Forecasts ($bn), 2012-2023Figure 4.7 Brazilian Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 4.8 Russian Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 4.9 Indian Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 4.10 Chinese Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 5.1 Global Market Shares (%) of the Main Companies in the Anti-Cancer Drugs Market, 2012Figure 5.2 Rituxan Sales Forecast ($bn), 2012-2023Figure 5.3 Herceptin Sales Forecast ($bn), 2012-2023Figure 5.4 Avastin Sales Forecast ($bn), 2012-2023Figure 5.5 Gleevec Sales Forecast ($bn), 2012-2023Figure 5.6 Revlimid Sales Forecast ($bn), 2012-2023Figure 5.7 Alimta Sales Forecast ($bn), 2012-2023Figure 5.8 Velcade Sales Forecast ($bn), 2012-2023Figure 5.9 Gardasil Sales Forecast ($bn), 2012-2023Figure 5.10 Xeloda Sales Forecast ($bn), 2012-2023Figure 5.11 Tarceva Sales Forecast ($bn), 2012-2023Figure 5.12 Sutent Sales Forecast ($bn), 2012-2023Figure 5.13 Zoladex Sales Forecast ($bn), 2012-2023Figure 5.14 Sprycel Sales Forecast ($bn), 2012-2023Figure 5.15 Nexavar Sales Forecast ($bn), 2012-2023Figure 5.16 Tasigna Sales Forecast ($bn), 2012-2023Figure 5.17 Eloxatin Sales Forecast ($bn), 2012-2023Figure 5.18 Temodar Sales Forecast ($bn), 2012-2023Figure 5.19 Vidaza Sales Forecast ($bn), 2012-2023Figure 5.20 Afinitor Sales Forecast ($bn), 2012-2023Figure 5.21 Xgeva Sales Forecast ($bn), 2012-2023Figure 5.22 Taxotere Sales Forecast ($bn), 2012-2023Figure 5.23 Yervoy Sales Forecast ($bn), 2012-2023Figure 5.24 Erbitux Sales Forecast ($bn), 2012-2023Figure 5.25 Faslodex Sales Forecast ($bn), 2012-2023Figure 5.26 Treanda Sales Forecast ($bn), 2012-2023Figure 7.1 Anti-Cancer Drug Market Shares (%) by Leading Company, 2012Figure 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2012Figure 11.1 Top 25 Anti-Cancer Drugs: Sales ($bn), 2012Companies ListedAbbott LaboratoriesAdvaxisAeterna ZentarisAgenusAlgetaAllerganAmbit BiosciencesAmerican Cancer SocietyAmgenAntitopeAPP PharmaceuticalsAriad PharmaceuticalsArQuleArray BioPharmaAstellas PharmaAstraZenecaAVEO PharmaceuticalsBayer HealthCareBaylor College of MedicineBioCancell TherapeuticsBiogen IdecBioniche Life SciencesBioVEXBiPar SciencesBoehringer IngelheimBioconBristol-Myers Squibb (BMS)Cancer AdvancesCelgeneCelldex TherapeuticsChugaiCiplaCyclacel PharmaceuticalsDaiichi SankyoDakoDan L. Duncan Cancer CenterDendreonDr. Reddy's LaboratoriesEisaiEleison PharmaceuticalsEli LillyEMD SeronoEndo PharmaceuticalsEuropean Medicines Agency (EMA)ExelixisFood and Drug Administration (US FDA)Galena BiopharmaGE HealthcareGenentechGenMabGentaGenzymeGlaxoSmithKline (GSK)HospiraImClone SystemsInovio PharmaceuticalsInternational Cancer Genome ConsortiumJanssen-CilagJohnson & Johnson (J&J)Keryx BiopharmaceuticalsLester and Sue Smith Breast Center, Baylor College of MedicineLpathMarshall EdwardsMcGill UniversityMedImmuneMedivationMenariniMerck & Co.Merck SeronoMillennium PharmaceuticalsMylanNational Cancer InstituteNational Health Service (UK)National Institute for Health and Clinical Excellence (NICE, UK)Nektar TherapeuticsNovartisOncoGenex PharmaceuticalsOnconova TherapeuticsOnyx PharmaceuticalsOSI PharmaceuticalsOtsukaOxford UniversityPfizerPharmaceutical Research and Manufacturers of America (PhRMA)PlexxikonProgen PharmaceuticalsProteolixPuma BiotechnologyRadientRegeneronRocheSandozSanofiSeattle GeneticsSkin Cancer FoundationSpectrum PharmaceuticalsSyndax PharmaceuticalsTactic PharmaTalon TherapeuticsTaiho Pharma USATakedaTenX BiopharmaTeva Pharmaceutical IndustriesTransgeneUCBUnited TherapeuticsVaccine CompanyWellstat BiologicsWilexWorld Health Organization (WHO)ZIOPHARM OncologyTo order this report: Leading Anti-Cancer Drugs and Associated Market 2013-2023 .reportlinker.com/p0819459/Leading-Anti-Cancer-Drugs-and-Associated-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication__________________________Contact Clare: clare@reportlinker.com US: (339)-368-6001Intl: +1 339-368-6001ReportlinkerWeb site: .reportlinker.com/新蒲崗迷你倉